- Home
- OCUL vs ZYME Comparison
OCUL vs ZYME Comparison
Compare OCUL & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCUL | ZYME |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2014 | 2022 |
Fundamental Metrics
Financial Performance| Metric | OCUL | ZYME |
|---|---|---|
| Price | $9.17 | $23.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $23.56 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 2.7M | 518.0K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | $1,990,000.00 | ★ $105,965,000.00 |
| Revenue This Year | $7.93 | $183.10 |
| Revenue Next Year | $96.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 3.48 | ★ 38.87 |
| 52 Week Low | $6.23 | $11.02 |
| 52 Week High | $16.44 | $29.75 |
Technical Indicators
Market Signals| Indicator | OCUL | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 36.43 |
| Support Level | $9.06 | $22.50 |
| Resistance Level | $9.93 | $27.54 |
| Average True Range (ATR) | 0.43 | 1.26 |
| MACD | -0.06 | -0.48 |
| Stochastic Oscillator | 23.67 | 7.10 |
Price Performance
Historical ComparisonAbout OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.